BMY Stock Price Today (September 2026) — Bristol-Myers Squibb Company Analysis & Key Metrics 2026-09-03
Bristol-Myers Squibb Company (BMY) is trading at $68.09, up 0.64% today (as of September 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $66.21 (-2.8% upside).
- Volatility remains elevated (19.82% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (5.70% YoY) alongside significant competitive pressures.
BMY Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Bristol-Myers Squibb Company - Historical Price & Volume
Market Cap
Enterprise Value: $169.99B
P/E Ratio
Forward P/E: 10.19
Revenue Growth
Year over Year
Analyst Target
+-2.8% upside potential
Key Investor Questions About BMY
What investors need to know before buying
Based on current market data, BMY presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 65.69)
- Fundamentals say: Caution warranted (high leverage concerns)
BMY's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for BMY investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $45.05B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, BMY stock traded between $42.52 and $68.64—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 19.82% annualized volatility and β=0.38, the stock exhibits low sensitivity to market moves—making BMY suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Drugmakers Halt Autoimmune Trials After Deaths, Life-Threatening Side Effects
Trial freezes by Novartis and Bristol Myers have triggered a race to understand why a promising autoimmune treatment turned risky.
Is Merck Stock Pricing In A Post-Keytruda Future Too Soon?
Merck’s stock is the top performer in its group, but its profitability sits at the very bottom of the pack, forcing a hard question on investors.
Summit Therapeutics Says It Is Beating Merck With Its Cancer Drug
Summit says its ivonescimab is keeping lung-cancer patients alive longer than Keytruda does. The stock is up.
ABBV Stock Has Returned $62 Billion To Shareholders. Should You Care?
A pharma giant delivered substantial cash returns to shareholders while outperforming the broader market. Here is a breakdown of AbbVie's cash-return capacity, and the key commercial metric supporting its durability.
Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector?
Despite Bristol-Myers Squibb's outperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.
Why Is Gilead (GILD) Up 13.6% Since Last Earnings Report?
Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services
Reviewing prior stock picks is how investors turn experience into valuable feedback. A recommendation is only a thesis until the market tests it. Watch Doug discuss recent stock picks, provide input on the current market environment—and take your questions.
What Does Bristol Myers Squibb (BMY) Trial Pause Mean For Its Pipeline?
Bristol Myers Squibb (NYSE:BMY) has paused enrollment in its zola-cel cell therapy trials for autoimmune conditions following emerging safety concerns. The voluntary pause comes after inflammatory side effects were detected during ongoing safety surveillance in the program. The move raises fresh questions around the risk profile of cell-based therapies in autoimmune diseases, as well as the pace of Bristol Myers Squibb's clinical pipeline. For readers interested in more ideas in this corner...
Amgen Stock Signals Its Confidence. The Market Agrees.
The real bet is on what lies beyond this year's performance: a pipeline that could change everything.
Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?
Cytokinetics' aficamten shows added benefits in HCM studies, strengthening its potential in non-obstructive and obstructive disease.
Explore More Analysis for BMY
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Bristol-Myers Squibb Company
Bristol-Myers Squibb Company (BMY) is currently trading at $68.09. The RSI (14-day) is at 65.7, indicating neutral territory. Wall Street analysts have a consensus "hold" recommendation. The mean analyst price target of $66.21 implies 2.8% downside from current levels. Volatility is low at 19.8% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Bristol-Myers Squibb Company (BMY): The trailing P/E ratio is 15.00, which is in line with broader market averages. The forward P/E is 10.19, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 2.37, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 6.23. Price-to-Sales is 2.83. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 24 analysts covering BMY, the consensus price target is $66.21. This represents a 2.8% downside from the current price of $68.09. The range spans from a low target of $40.00 to a high target of $80.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Bristol-Myers Squibb Company (BMY) pays a dividend with a current yield of approximately 3.70%. The annualized dividend rate is $2.51 per share. The payout ratio is 55.3%, which is moderate and suggests adequate earnings coverage for the dividend. The most recent ex-dividend date was 2026-07-02T00:00:00.000Z.
Key risks for Bristol-Myers Squibb Company (BMY) investors include: 1. Elevated debt levels (D/E ratio of 201.86) which could pressure margins in a rising rate environment. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Bristol-Myers Squibb Company's (BMY) current debt and financial health profile: Total debt stands at $45.05B. The debt-to-equity ratio is 201.86, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 1.53, indicating strong short-term liquidity. The quick ratio is 1.29. The company holds $11.07B in cash and equivalents. Free cash flow is positive at $8.11B, providing a cushion for debt servicing and shareholder returns.